Amila Patel
Overview
Explore the profile of Amila Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramkumar S, Bhardwaj A, Patel A, Seetharaman K, Christman A, Amondikar N, et al.
JAMA Otolaryngol Head Neck Surg
. 2023 Aug;
149(10):912-918.
PMID: 37651149
Importance: The US Food and Drug Administration approved immune checkpoint inhibitors (immunotherapy) for select cases of head and neck squamous cell carcinoma (HNSCC) in 2016. However, it is unclear whether...
2.
McKelvey B, Berk A, Chin L, Hudgens S, Kudel I, OHagan R, et al.
JCO Clin Cancer Inform
. 2023 Feb;
7:e2200161.
PMID: 36821804
Purpose: Using patient-reported outcomes (PROs) provides important insights from the patient's perspective and can be valuable to monitor and manage treatment-related adverse events during cancer treatment. Additionally, the digital administration...
3.
Canick J, Bhardwaj A, Patel A, Kuziez D, Larsen R, Misra S, et al.
JCO Oncol Pract
. 2022 Dec;
19(3):e397-e406.
PMID: 36480772
Purpose: While pain is prevalent among survivors of head and neck cancer (HNC), there is a lack of data on pain management in the community oncology setting. We described sociodemographic...
4.
Patt D, Wilfong L, Hudson K, Patel A, Books H, Pearson B, et al.
JCO Clin Cancer Inform
. 2021 Jun;
5:615-621.
PMID: 34085537
Purpose: Among patients receiving chemotherapy, symptom monitoring with electronic patient-reported outcomes (ePROs) is associated with improved clinical outcomes, satisfaction, and compliance with therapy. Standard approaches for ePRO implementation are not...
5.
Floeter A, Patel A, Tran M, Chamberlain M, Hendrie P, Gopal A, et al.
Clin Lymphoma Myeloma Leuk
. 2017 Feb;
17(4):225-230.
PMID: 28169156
Introduction: The purpose of our study was to identify the key risk factors for the development of posterior reversible encephalopathy syndrome (PRES) after administration of the combination chemotherapy regimen, DA-EPOCH...
6.
Baz R, Miladinovic B, Patel A, Ho V, Shain K, Alsina M, et al.
Leuk Res
. 2013 Jul;
37(9):1077-82.
PMID: 23809054
Lenalidomide and bortezomib have not been compared prospectively and are currently used in sequence for patients with multiple myeloma; however, it is unknown whether a sequence of administration could result...
7.
Patel A, Patel J, Ikwuagwu J
J Antimicrob Chemother
. 2010 Oct;
65(12):2489-92.
PMID: 20961908
Progressive multifocal leukoencephalopathy is a neurological disease caused by the human polyoma virus JC virus and can present in patients with known immunodeficiencies. However, when associated with idiopathic CD4+ lymphocytopenia,...
8.
Patel A, Patel J, Ikwuagwu J
J Antimicrob Chemother
. 2010 Sep;
65(12):2697-8.
PMID: 20864499
No abstract available.